• +1-646-491-9876
    • +91-20-67278686

    Search

    Systemic Sclerosis Pipeline Review H2 2017

    Systemic Sclerosis Pipeline Review H2 2017

    • Report Code ID: RW0001884159
    • Category Pharmaceuticals
    • No. of Pages 225
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2017, provides an overview of the Systemic Sclerosis (Scleroderma) (Immunology) pipeline landscape.

    Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pains, joint pain and swelling, ulcers occurring on fingertips, bloating of the tummy and diarrhea or constipation. Treatment includes antibiotic, pain relievers and immunosuppressant.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 14, 5, 22 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

    Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma) (Immunology) .
    - The pipeline guide reviews pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Systemic Sclerosis (Scleroderma) (Immunology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Systemic Sclerosis (Scleroderma) (Immunology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) (Immunology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 5
    List of Figures 6
    Introduction 7
    Publisher Report Coverage 7
    Systemic Sclerosis (Scleroderma) - Overview 8
    Systemic Sclerosis (Scleroderma) - Therapeutics Development 9
    Pipeline Overview 9
    Pipeline by Companies 10
    Pipeline by Universities/Institutes 14
    Products under Development by Companies 15
    Products under Development by Universities/Institutes 18
    Systemic Sclerosis (Scleroderma) - Therapeutics Assessment 19
    Assessment by Target 19
    Assessment by Mechanism of Action 23
    Assessment by Route of Administration 27
    Assessment by Molecule Type 29
    Systemic Sclerosis (Scleroderma) - Companies Involved in Therapeutics Development 31
    Allergan Plc 31
    AnaMar AB 31
    Angion Biomedica Corp 32
    arGentis Pharmaceuticals LLC 32
    Bayer AG 33
    Biogen Inc 33
    BLR Bio LLC 34
    Boehringer Ingelheim GmbH 34
    Bristol-Myers Squibb Company 35
    Covis Pharmaceuticals Inc 35
    CSL Ltd 36
    Cumberland Pharmaceuticals Inc 36
    F. Hoffmann-La Roche Ltd 37
    Fibrocell Science Inc 37
    GenKyoTex SA 38
    Gilead Sciences Inc 38
    GlaxoSmithKline Plc 39
    iBio Inc 39
    Inventiva 40
    Leadiant Biosciences Inc 40
    MedImmune LLC 41
    Patagonia Pharmaceuticals LLC 41
    PDX Pharmaceuticals LLC 42
    Peptinov SAS 42
    ProMetic Life Sciences Inc 43
    Ribomic Inc 43
    Samumed LLC 44
    Sanofi 44
    Seattle Genetics Inc 45
    Stemline Therapeutics Inc 45
    Stratatech Corp 46
    Vicore Pharma AB 46
    viDA Therapeutics Inc 47
    VivaCell Biotechnology Espana SL 47
    Systemic Sclerosis (Scleroderma) - Drug Profiles 48
    abatacept - Drug Profile 48
    acALY-18 - Drug Profile 56
    ambrisentan - Drug Profile 57
    anabasum - Drug Profile 60
    ANG-3070 - Drug Profile 68
    ARG-201 - Drug Profile 69
    belimumab - Drug Profile 71
    BLR-200 - Drug Profile 78
    brentuximab vedotin - Drug Profile 79
    C-1889 - Drug Profile 106
    C-21 - Drug Profile 108
    C-82 - Drug Profile 111
    Cell Therapy for Dermatology and Immunology - Drug Profile 112
    CM-101 - Drug Profile 114
    dimethyl fumarate DR - Drug Profile 115
    elapegademase - Drug Profile 120
    factor XIII (human) - Drug Profile 121
    FCX-013 - Drug Profile 122
    GKT-831 - Drug Profile 123
    GSK-2330811 - Drug Profile 127
    IBIOCFB-03 - Drug Profile 128
    ifetroban sodium - Drug Profile 130
    IVA-337 - Drug Profile 132
    M-10 - Drug Profile 134
    MEDI-7734 - Drug Profile 135
    miRNA-29 - Drug Profile 136
    Monoclonal Antibodies to Antagonize IL-3RA for Autoimmune Disorders - Drug Profile 137
    nintedanib - Drug Profile 138
    nitroglycerin - Drug Profile 149
    onabotulinumtoxinA - Drug Profile 151
    PAT-048 - Drug Profile 156
    PATS-03 - Drug Profile 157
    PBI-4050 - Drug Profile 158
    PBI-4425 - Drug Profile 166
    PDX-002 - Drug Profile 167
    PPV-06 - Drug Profile 168
    RBM-006 - Drug Profile 169
    riociguat - Drug Profile 170
    rituximab biosimilar - Drug Profile 176
    RP-182 - Drug Profile 177
    SAR-100842 - Drug Profile 178
    SAR-156597 - Drug Profile 179
    SAR-317461 - Drug Profile 180
    SM-04755 - Drug Profile 181
    Small Molecule to Inhibit NFkB for Autoimmune Disorders, Melanoma and Inflammation - Drug Profile 183
    Small Molecules to Antagonize 5-HT2B for Idiopathic Pulmonary Fibrosis and Systemic Sclerosis - Drug Profile 184
    sodium nitrite SR - Drug Profile 185
    Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis - Drug Profile 187
    terguride - Drug Profile 188
    tocilizumab - Drug Profile 189
    TRX-101 - Drug Profile 199
    VCE-0048 - Drug Profile 200
    VEDA-1209 - Drug Profile 201
    VTI-1000 Series - Drug Profile 202
    Wnt-001 - Drug Profile 203
    Systemic Sclerosis (Scleroderma) - Dormant Projects 204
    Systemic Sclerosis (Scleroderma) - Discontinued Products 206
    Systemic Sclerosis (Scleroderma) - Product Development Milestones 207
    Featured News & Press Releases 207
    Appendix 220
    Methodology 220
    Coverage 220
    Secondary Research 220
    Primary Research 220
    Expert Panel Validation 220
    Contact Us 220
    Disclaimer 221

    List of Tables

    Number of Products under Development for Systemic Sclerosis (Scleroderma) , H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..1) , H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..2) , H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017 (Contd..1) , H2 2017
    Products under Development by Companies, H2 2017 (Contd..2) , H2 2017
    Products under Development by Universities/Institutes, H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Target, H2 2017 (Contd..1) , H2 2017
    Number of Products by Stage and Target, H2 2017 (Contd..2) , H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1) , H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2) , H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Allergan Plc, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by AnaMar AB, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Angion Biomedica Corp, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by arGentis Pharmaceuticals LLC, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Bayer AG, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Biogen Inc, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by BLR Bio LLC, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Boehringer Ingelheim GmbH, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Bristol-Myers Squibb Company, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Covis Pharmaceuticals Inc, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by CSL Ltd, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Cumberland Pharmaceuticals Inc, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Fibrocell Science Inc, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by GenKyoTex SA, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Gilead Sciences Inc, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by GlaxoSmithKline Plc, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by iBio Inc, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Inventiva, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Leadiant Biosciences Inc, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by MedImmune LLC, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Patagonia Pharmaceuticals LLC, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by PDX Pharmaceuticals LLC, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Peptinov SAS, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by ProMetic Life Sciences Inc, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Ribomic Inc, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Samumed LLC, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Sanofi, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Seattle Genetics Inc, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Stemline Therapeutics Inc, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Stratatech Corp, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Vicore Pharma AB, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by viDA Therapeutics Inc, H2 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by VivaCell Biotechnology Espana SL, H2 2017
    Systemic Sclerosis (Scleroderma) - Dormant Projects, H2 2017
    Systemic Sclerosis (Scleroderma) - Dormant Projects, H2 2017 (Contd..1) , H2 2017
    Systemic Sclerosis (Scleroderma) - Discontinued Products, H2 2017

    List of Figures

    Number of Products under Development for Systemic Sclerosis (Scleroderma) , H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products by Top 10 Targets, H2 2017
    Number of Products by Stage and Top 10 Targets, H2 2017
    Number of Products by Top 10 Mechanism of Actions, H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Molecule Types, H2 2017
    Number of Products by Stage and Molecule Types, H2 2017
    Allergan Plc
    AnaMar AB
    Angion Biomedica Corp
    arGentis Pharmaceuticals LLC
    Bayer AG
    Biogen Inc
    BLR Bio LLC
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Company
    Covis Pharmaceuticals Inc
    CSL Ltd
    Cumberland Pharmaceuticals Inc
    F. Hoffmann-La Roche Ltd
    Fibrocell Science Inc
    GenKyoTex SA
    Gilead Sciences Inc
    GlaxoSmithKline Plc
    iBio Inc
    Inventiva
    Leadiant Biosciences Inc
    MedImmune LLC
    Patagonia Pharmaceuticals LLC
    PDX Pharmaceuticals LLC
    Peptinov SAS
    ProMetic Life Sciences Inc
    Ribomic Inc
    Samumed LLC
    Sanofi
    Seattle Genetics Inc
    Stemline Therapeutics Inc
    Stratatech Corp
    Vicore Pharma AB
    viDA Therapeutics Inc
    VivaCell Biotechnology Espana SL

    Request for Sample

    Report Url http://www.reportsweb.com//systemic-sclerosis-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//systemic-sclerosis-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//systemic-sclerosis-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments